 |
市場調查報告書
商品編碼
2039010
皮膚鱗狀細胞癌治療市場：依治療方法、應用和地區分類Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment, By Application, By Geography |
||||||
2026年皮膚鱗狀細胞癌治療市場規模估計為158億美元，預計2033年將達到258億美元。預計2026年至2033年，該市場將以7.2%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 158億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 7.20% | 2033年市場規模預測： | 258億美元 |
皮膚鱗狀細胞癌（cSCC）是一種常見的皮膚癌，屬於角質形成細胞癌或非黑色素瘤皮膚癌。它起源於表皮中產生角質蛋白的細胞，角蛋白是構成皮膚、毛髮和指甲的蛋白質。皮膚鱗狀細胞癌（cSCC）是一種侵襲性疾病，指的是癌細胞已突破表皮層生長。紫外線（UV）輻射是皮膚鱗狀細胞癌發生的主要危險因子。
市場動態
皮膚鱗狀細胞癌（cSCC）發生率的上升預計將推動cSCC治療市場的成長。例如，根據美國國家生物技術資訊中心（NCBI）2020年8月發表的報導，鱗狀細胞癌是美國第二大常見皮膚癌，僅次於基底細胞癌。另有通報稱，美國每年新增鱗狀細胞癌病例超過一百萬例。
然而，皮膚鱗狀細胞癌（cSCC）診療指南缺乏標準化，給醫生實施治療帶來了挑戰，預計這將阻礙市場成長。例如，美國國家生物技術資訊中心（NCBI）在2020年8月發表的一篇論文指出，醫生面臨的挑戰在於如何根據腫瘤和宿主特徵，準確評估患者的疾病進行性風險。
本次調查的主要特點
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新藥上市和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的關鍵見解。
- 本研究根據以下參數對全球鱗狀細胞癌治療市場的主要參與者進行了分析：公司概況、財務績效、產品系列、市場佔有率、分銷策略、主要發展、策略和未來計劃。
- 透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的藥物上市、藥物類別升級、市場擴張和行銷策略做出明智的決策。
- 《全球皮膚鱗狀細胞癌治療市場》報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用分析全球鱗狀細胞癌治療市場中使用的各種策略矩陣，更輕鬆地做出決策。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場範圍
- 報告摘要
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機遇
- 影響分析
- 管道分析
- 救贖方案
- 流行病學
- PEST分析
- 監管情景
- 新產品發布
- 合作關係與協議
- 市場趨勢
第4章 全球皮膚鱗狀細胞癌治療市場：依治療方法分類，2021-2033年
- 手術治療
- 非手術
第5章 全球皮膚鱗狀細胞癌治療市場：依應用領域分類，2021-2033年
- 醫院
- 癌症專科醫療機構
- 門診手術中心
- 其他
第6章 全球皮膚鱗狀細胞癌治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 南非
- 中非
- 北非
第7章 競爭情勢
- 熱圖分析
- 市佔率分析
- Eli Lilly and Company
- Sanofi SA
- Cadila Healthcare Limited
- Cipla Limited
- Castle Biosciences
- Regeneron Pharmaceuticals, Inc
- Merck &Co., Inc
- Vidac Pharma
- LEO Pharma A/S
- Regeneron Pharmaceuticals, Inc.
- Merck Sharp &Dohme
- Amgen Inc.
第8章
- 參考
- 調查方法
Cutaneous Squamous Cell Carcinoma Treatment Market is estimated to be valued at USD 15,800 Mn in 2026 and is expected to reach USD 25,800 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 15,800 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.20% | 2033 Value Projection: | USD 25,800 Mn |
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer grouped in the class of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin, the protein which makes up skin, hair, and nails. Cutaneous squamous cell carcinoma (cSCC) is an invasive disease, referring to cancer cells that have grown beyond the epidermis. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma.
Market Dynamics
Rising incidence of cutaneous squamous cell carcinoma (cSCC) is expected to drive cutaneous squamous-cell carcinoma treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S followed by basal cell carcinoma. It also reports that over one million squamous cell carcinoma cases are diagnosed in the U.S. each year.
However, lack of standardization in the guidelines for cutaneous squamous cell carcinoma (cSCC) creates a challenge for physicians to execute the treatment, and this is expected to hinder the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that physician's challenge lies in properly assessing a patient's risk for aggressive disease based on tumor or host characteristics.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cutaneous squamous-cell carcinoma treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global cutaneous squamous-cell carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cutaneous squamous-cell carcinoma treatment market.
Cutaneous Squamous Cell Carcinoma Treatment Market Segmentation
- By Treatment Insights
- Surgical
- Moh's Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application Insights
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Region Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players in the Cutaneous Squamous Cell Carcinoma Treatment Market
- Eli Lilly and Company
- Sanofi S.A.
- Cadila Healthcare Limited
- Cipla Limited
- Castle Biosciences
- Regeneron Pharmaceuticals, Inc
- Merck & Co., Inc
- Vidac Pharma
- LEO Pharma A/S
- Merck Sharp & Dohme
- Amgen Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- Regulatory Scenario
- New Product Launches
- Collaborations and Agreements
- Market Trends
4. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Surgical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Moh's Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
5. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Application, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Cancer Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- North America
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cadila Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cipla Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Castle Biosciences
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Regeneron Pharmaceuticals, Inc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Vidac Pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- LEO Pharma A/S
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck Sharp & Dohme
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Eli Lilly and Company
8. Section
- References
- Research Methodology
- About us and Sales Contact
